Funding for this research was provided by:
Canadian Institutes of Health Research (01308-000)
Received: 17 April 2019
Accepted: 7 August 2019
First Online: 5 September 2019
Ethics approval and consent to participate
: Research Ethics Board approval was received from the Douglas Mental Health University Institute (IUSMD-15-21), followed by institutional ethics approval from participating ACCESS Open Minds sites, where needed. Any important modifications to protocol will be notified to the Douglas ethics board, ethics boards for other institutions pertaining to participating sites, trial registry, funding bodies and the journal in which the protocol is published.At all sites, youth above the age of 18 are approached for written informed consent. For minors below the age of 14 or youth with diminished capacity, consent is sought from a parent/legal representative along with assent from the young person. Provincial/institutional regulations vary in terms of policy around the need for consent from a parent/legal representative in the case of youth between the ages of 14 and 18 (see Additional file InternalRef removed).
: Not applicable.
: Ridha Joober is a speaker and/or consulting committee member for Janssen, Lundbeck, Myelin, Otsuka, Perdue, Pfizer, Shire, and Sunovian; has received grants from Astra Zeneca, BMS, HLS, Janssen, Lundbeck, and Otsuka; and has royalties from Henry Stewart talks. Ashok K. Malla reports research funding for an investigator-initiated project from BMS Canada and honoraria for lectures and consulting activities with Lundbeck and Otsuka. For both authors, none of the funds received have any relation to this manuscript. The other authors report no competing interests.